106500-25-8
106500-25-8 結(jié)構(gòu)式
基本信息
Deacetylazadirachtinol
7H,8H-Furo[3',4':4,4a]naphtho[1,8-bc]furan-5,10a(1H)-dicarboxylic acid, octahydro-3,8-dihydroxy-4-methyl-10-[[(2E)-2-methyl-1-oxo-2-buten-1-yl]oxy]-4-[(1aR,2S,3aS,6aS,7S,7aS)-3a,6a,7,7a-tetrahydro-6a-hydroxy-7a-methyl-2,7-methanofuro[2,3-b]oxireno[e]oxepin-1a(2H)-yl]-, 5,10a-dimethyl ester, (2aR,3S,...
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-133108 | 印楝素B Azadirachtin B | 106500-25-8 | 1 mg | 1500元 |
| 2026/06/05 | HY-133108 | 印楝素B Azadirachtin B | 106500-25-8 | 5 mg | 3745元 |
常見問題列表
Plutella xylostella
Alkaline phosphatase (ALP)
Epstein-Barr virus early antigen (EBV-EA)
Azadirachtin B (1 pM-100 μM; 48 hours; Osteoblast cells) treatment shows highest proliferation at 10 nM and 100 pM concentrations in osteoblast cells.
Azadirachtin B increases expression of RunX-2 ～2.5 fold at 10 nM concentration, ALP expression ～2.8 fold at 10 nM and 100 pM concentration and OCN expression ～2.5 folds at 10 nM as compared with control.
Azadirachtin B (Compound 4) exhibits toxicity to the diamondback moth (
Plutella xylostella
) with an LD
50
of 4.85-1.06 μg/g body weight, in 92 h.
Azadirachtin B (compound 21) exhibits moderate or potent inhibitory effects (IC50 value of 384 mol ratio/32 pmol TPA) against the Epstein-Barr virus early antigen (EBV-EA) activation induced by tetradecanoylphorbol-13-acetate (TPA).
Cell Proliferation Assay
| Cell Line: | Osteoblast cells |
| Concentration: | 1 pM, 100 pM, 10 nM, 1 μM, 100 μM |
| Incubation Time: | 48 hours |
| Result: | Showed highest proliferation at 10 nM and 100 pM concentrations in osteoblast cells. |
On evaluation of Azadirachtin B (compound 21; oral administration) for its anti-tumor-initiating activity on the two-stage carcinogenesis of mouse skin tumor induced by peroxynitrite (ONOO-; PN) as an initiator and TPA as a promoter, this exhibited marked inhibitory activity.